EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

Xinai Shen iD, Huan Li iD, Beiyu Zhang, Yunan Li iD, Zheying Zhu iD

Cells · 26.09.2025 · 14 (19) · 1506

DOI: 10.3390/cells14191506 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.09.2025. Verfasst von Xinai Shen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Therapeutics and Formulation, School of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK. Hauptthemen laut MEDLINE: tau Proteins, Molecular Targeted Therapy, Alzheimer Disease, Tauopathies. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Nottingham, the School of Pharmacy, The University of Nottingham.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tau protein, a neuron-enriched microtubule-associated protein encoded by the MAPT gene, plays pivotal roles in microtubule stabilisation, axonal transport, and synaptic plasticity. Aberrant post-translational modifications (PTMs), hyperphosphorylation, acetylation, ubiquitination, oxidative stress and neuroinflammation disrupt tau’s normal functions, drive its mislocalization, and promote aggregation into neurofibrillary tangles, a hallmark of Alzheimer’s disease (AD) and related tauopathies. Over the past two decades, tau-targeted therapies have advanced into clinical development, yet most have failed to demonstrate efficacy in human trials. This review synthesises mechanistic insights into tau biology and pathology, highlighting phosphorylation and acetylation pathways, aggregation-prone motifs, and immune-mediated propagation. We analyse the current therapeutic landscape, including kinase and phosphatase modulators, O-GlcNAcase inhibitors, aggregation blockers, immunotherapies, and microtubule-stabilising agents, while examining representative clinical programs and the reasons underlying their limited success. By combining mechanistic understanding with clinical experience, this review outlines emerging opportunities for rational treatment development, aiming to inform future tau-targeted strategies for AD and other tauopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsMolecular Targeted TherapyAlzheimer DiseaseTauopathiesHumansAnimalsProtein Processing, Post-TranslationalPhosphorylation

Stichwörter der Autor:innen

Alzheimer’s diseaseclinical trialstau proteintauopathies

Substanzen

tau Proteins

Autor:innen und Institutionen

  • Division of Molecular Therapeutics and Formulation, School of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.

ORCID-Profile: Xinai Shen, Huan Li, Yunan Li, Zheying Zhu

Förderung

  • University of Nottingham
  • the School of Pharmacy, The University of Nottingham

Zitieren

APA

Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025). Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures. Cells, 14(19), 1506. https://doi.org/10.3390/cells14191506

Vancouver

Shen X, Li H, Zhang B, Li Y, Zhu Z. Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures. Cells. 2025;14(19):1506. doi:10.3390/cells14191506

BibTeX
@article{Shen2025,
  author = {Shen, Xinai and Li, Huan and Zhang, Beiyu and Li, Yunan and Zhu, Zheying},
  title = {Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {19},
  pages = {1506},
  doi = {10.3390/cells14191506}
}
Kostenlos starten →